• Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China;
Ye Junjie, Email: yejunjie_xh@163.com
Export PDF Favorites Scan Get Citation

Intraocular tumors is a serious blinding eye disease, which has a serious impact on patients' vision and even life. At present, the main treatments include surgical treatment, radiation therapy, chemotherapy, laser therapy and combination therapy. In recent years, with the wide application of anti-vascular endothelial growth factor (VEGF) in the treatment of ocular diseases, many studies have confirmed that anti-VEGF drugs play an important auxiliary role in the treatment of intraocular tumors and its complications. In terms of the therapeutic effect, intravitreal anti-VEGF combined with other methods have a good prognosis in the treatment of choroidal metastatic carcinoma and retinoblastoma, while the therapeutic effect of uveal melanoma is still controversial. In the treatment of intraocular tumor complications, intravitreal anti-VEGF also has a good effect on the secondary lesions of choroidal osteoma and radiation retinopathy. As for drug safety, intravitreal anti-VEGF can significantly reduce the toxic and side effects of systemic chemotherapeutic therapy. However, the dosage and medication regimen of anti-VEGF drugs in the treatment of intraocular tumors and their complications have not been unified in current studies, and further basic and clinical trials are still needed to explore in the future.

Citation: Di Yu, Ye Junjie. Research advances on anti-vascular endothelial growth factor in the treatment of intraocular tumors and its complications. Chinese Journal of Ocular Fundus Diseases, 2022, 38(10): 857-861. doi: 10.3760/cma.j.cn511434-20210709-00369 Copy

  • Previous Article

    视网膜分支静脉阻塞并视盘新生血管
  • Next Article

    Research progress of Müller cell and macular hole